The domino effect: What happens when migraine treatments block the CGRP pathway?
An ever-growing body of evidence suggests that calcitonin gene-related peptide (CGRP) plays a crucial role in the pathophysiology of migraine.1 Indeed, CGRP is released during acute migraine attacks2 and the intravenous infusion of CGRP in patients with migraine acts as a trigger for migraine attacks.3 These insights led researchers to consider CGRP and its rece
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.
Log InNot registered yet? Register now